Multi-analyte assays and early detection of common cancers

The clinical use of biomarker assays to identify cancers, at a sufficiently early enough stage to enable a surgical cure, remains the “Holy Grail” of cancer diagnostics (1). Progress in various bio-assays, especially with liquid biopsies using molecular genetic markers (2), has excited the research community although their adoption in routine clinical practice remains elusive.